A Los Angeles jury ordered Johnson & Johnson to pay $966 million to the family of a California resident who died of a rare form of cancer. The family filed a suit against the company claiming that its baby powder contains a carcinogen. Mae Moore died in 2021 from mesothelioma, cancer of the mesothelium –…
NJ sues Pfizer and others for water contamination
New Jersey’s Department of Environmental Protection (DEP) has filed a lawsuit against Pfizer, Johnson & Johnson, Honeywell and several real estate companies, claiming there is toxic waste on an old pharmaceutical plant site, contaminating the groundwater. The plant, located in Morris Plains, was operational from the 1950s to the 1980s under Warner-Lambert, which Pfizer acquired…
Roche, Novartis lead 2024’s top 50 pharma in oncology (YTD)
Swiss pharma giants Novartis and Roche consistently rank among the top pharma companies in terms of revenue. In 2024, the two companies are also leading in total international patent volume. Meanwhile, smaller firms like Incyte and Vertex Pharma are punching above their weight in market impact. For instance, Incyte, with a market cap of just…
How the FDA approval of J&J’s Opsynvi could simplify treatment and improve outcomes for PAH patients
Pulmonary arterial hypertension (PAH), a rare, progressive and life-threatening blood vessel disorder, affects some 500 to 1,000 new patients each year in the U.S. FDA recently approved Opsynvi, a first-of-its-kind once-daily single-tablet combination therapy from Johnson & Johnson. “With this approval, our portfolio now includes treatments that address all three guideline-recommended pathways,” said a J&J…
Are Big Pharma giants getting the right ROI on their R&D investments? A visual exploration
While annual reports show broadly similar R&D strategies among Merck & Co., Pfizer, Johnson & Johnson and AbbVie, their 2020–2023 financial metrics reveal a concerning trend. Merck & Co. may be the new top dog of Big Pharma, but the firm’s 1.4% revenue growth in 2023 represents a significant slowdown. Pfizer’s 41.7% revenue decline from…
Johnson & Johnson launches research partnerships network
Johnson & Johnson (NYSE:JNJ) announced today that it has launched the J&J Centers for Global Health Discovery, a global network of research partnerships to address the world’s health challenges. The first J&J Satellite Center for Global Health Discovery is at the London School of Hygiene & Tropical Medicine. The pharma and medtech giant plans to…
Vaccine panel postpones vote on J&J COVID-19 vaccine
A CDC advisory committee decided not to vote on how Johnson & Johnson’s COVID-19 vaccine should be deployed, reasoning that it needs more time to review data related to rare blood clots potentially linked to the vaccine. The CDC and FDA announced on April 13 their recommendation to pause the vaccine’s use on safety grounds.…
FDA authorizes J&J’s single-dose COVID-19 vaccine
Americans will start receiving Johnson & Johnson‘s COVID-19 vaccine within the next 24 to 48 hours, J&J CEO Alex Gorsky told NBC’s Today this morning. FDA issued an EUA for J&J’s Ad26.COV2-S vaccine on Feb. 27, a day after an advisory panel unanimously recommended that the agency authorize the vaccine for adults 18 and over.…
Is J&J’s COVID-19 vaccine linked to tinnitus?
In Johnson & Johnson’s (NYSE:JNJ) Phase 3 trial for the Ad26.COV2.S COVID-19 vaccine, six vaccine recipients developed tinnitus or ringing in the ears. In five of those individuals, tinnitus had either resolved or was resolving. The condition was unresolved in the other trial volunteer. No placebo recipients developed the condition. J&J concluded that the tinnitus reports…